PNEUMAGEN
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.
PNEUMAGEN
Social Links:
Industry:
Biotechnology Health Care Wellness
Founded:
2016-01-01
Address:
Saint Andrews, Fife, United Kingdom
Country:
United Kingdom
Website Url:
http://www.pneumagen.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
18.3 M GBP
Similar Organizations
Achilles Therapeutics
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.
Pandion Therapeutics
Pandion Therapeutics develops innovative modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Thairm Bio
Thairm Bio investment in Venture Round - Pneumagen
Esperante Ventures
Esperante Ventures investment in Venture Round - Pneumagen
Scottish Enterprise
Scottish Enterprise investment in Venture Round - Pneumagen
Scottish Enterprise
Scottish Enterprise investment in Venture Round - Pneumagen
Thairm Bio
Thairm Bio investment in Venture Round - Pneumagen
Thairm Bio
Thairm Bio investment in Venture Round - Pneumagen
Scottish Investment Bank
Scottish Investment Bank investment in Venture Round - Pneumagen
Scottish Investment Bank
Scottish Investment Bank investment in Venture Round - Pneumagen
Equity Gap
Equity Gap investment in Venture Round - Pneumagen
Thairm Bio
Thairm Bio investment in Venture Round - Pneumagen
Official Site Inspections
http://www.pneumagen.com Semrush global rank: 13.01 M Semrush visits lastest month: 78
- Host name: server.ncserver.co.uk
- IP address: 62.100.204.187
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "Pneumagen"
About Us - Pneumagen
Pneumagen is a clinical-stage biotech company developing Neumifil, ... of the Department of Infectious diseases at St Jude Children’s Research Hospital and Director of the World Health …See details»
Pneumagen - Crunchbase Company Profile & Funding
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and …See details»
PNEUMAGEN LIMITED - LinkedIn
PNEUMAGEN LIMITED | 772 followers on LinkedIn. Pneumagen is treating infectious diseases by targeting the human glycome. | PNEUMAGEN LIMITED is a biotechnology company based …See details»
Tour of Scotland: St. Andrews based Pneumagen aims to prevent …
Mar 13, 2025 Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. …See details»
Pneumagen 2025 Company Profile: Valuation, Funding & Investors …
Pneumagen was founded in 2016. Where is Pneumagen headquartered? Pneumagen is headquartered in Saint Andrews, United Kingdom. What is the size of Pneumagen? …See details»
Investors - Pneumagen
In addition to Neumifil, Pneumagen is harnessing this technology to develop a pipeline of additional therapies targeting other infectious diseases. Following positive Phase I data, a …See details»
Pneumagen - Products, Competitors, Financials, Employees, …
Pneumagen is a clinical-stage biotech company focused on developing broad-spectrum antiviral therapies for the prevention and treatment of viral respiratory tract infections. Its lead product, …See details»
Pneumagen Company Profile - Office Locations, Competitors
Pneumagen has 1 employees at their 1 location and $8.33 m in total funding,. See insights on Pneumagen including office locations, competitors, revenue, financials, executives, …See details»
Pneumagen - The Org
Pneumagen develops glycan targeted carbohydrate binding modules (CBMs) for respiratory tract infections ) and cancer. Industries. Biotechnology, Health & Wellness +1. Headquarters. Saint …See details»
Pneumagen Company Profile | Management and Employees List
Pneumagen's lead product, Neumifil, is a first-in-class mCBM40 being developed for the universal treatment of Influenza Virus (IFV), Respiratory Syncytial Virus (RSV), and coronavirus COVID …See details»
Pneumagen - Contacts, Employees, Board Members, Advisors
Organization. Pneumagen . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. Number of Board …See details»
Pneumagen - Crustdata Company Profile, Funding and Growth
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and …See details»
Press Release – Pneumagen
Jul 3, 2024 Pneumagen Douglas Thomson, CEO. Email: [email protected] . MEDiSTRAVA Consulting (Financial PR) Frazer Hall, David Dible, Sandi Greenwood. Email: Pneumagen@ …See details»
Home - Omideon
Douglas Thomson is a non-executive director at Omideon. In other roles he is Chief Executive Officer and a co-founder at Pneumagen, a clinical-stage anti-viral business. Previously, he has …See details»
Pneumagen - Portfolio Company Profile, Executives and Private …
Pneumagen is focused on treating respiratory tract infections and other infectious diseases and oncology by targeting the human glycome. See Pneumagen's complete profile, including its …See details»
Pneumagen - Funding, Financials, Valuation & Investors
Pneumagen develops glycan targeted carbohydrate binding modules (CBMs) for respiratory tract infections ) and cancer. New. Resources. Advanced Search. ... How much funding has this …See details»
Pneumagen - Eden Scott
Pneumagen is a clinical-stage biotech company developing Neumifil, a broad-spectrum antiviral, as an intranasal drug for the prophylaxis of a wide range of viral respiratory tract infections …See details»
Pneumagen appoints James Noble, a highly experienced biotech …
Jan 6, 2023 James Noble added “I am honoured to take on the role as Chairman of the Board of Directors at Pneumagen, a company that has already delivered highly encouraging early …See details»
News & Events – Pneumagen
Jan 6, 2023 Pneumagen Highlights Broad-Spectrum Antiviral Activity of First-in-Class Intranasal Drug Neumifil in New Publication. READ MORE... 23 May, 2024. Pneumagen Presents …See details»